What biomarker testing is recommended for metastatic Multiple Myeloma

Biomarker Testing for Multiple Myeloma

I'll walk you through the key biomarker tests that are recommended at diagnosis and during treatment monitoring for multiple myeloma. These tests help your care team understand your disease and plan the best treatment approach.

Essential Biomarker Tests at Diagnosis

According to the NCCN Guidelines for Multiple Myeloma, your initial workup should include several important biomarker assessments:

Blood Protein Markers

M Protein (Monoclonal Protein) Testing:

• Serum Protein Electrophoresis (SPEP) - measures the amount of abnormal M proteins in your blood
• Serum Immunofixation Electrophoresis (SIFE) - identifies the type of M protein (which heavy chain: IgG, IgA, IgM, IgD, or IgE; and which light chain: kappa or lambda)

These tests are crucial because M proteins are the "signature" of your myeloma cells. Tracking M protein levels over time shows how well treatment is working.

Free Light Chain (FLC) Assay:

• Measures free light chains circulating in your blood
• Particularly important if your myeloma produces only light chains
• Used to calculate the FLC ratio, which is required to document complete response to treatment

Immunoglobulin Levels:

• Measures total antibody levels (IgA, IgG, IgM)
• Shows if antibody levels are abnormally high or low

Kidney and Organ Function Markers

The NCCN Guidelines recommend these tests because myeloma commonly damages kidneys:

• Serum creatinine and BUN - assess kidney function
• Creatinine clearance - calculated or measured directly
• Serum calcium - myeloma can cause dangerously high calcium levels
• Serum uric acid - elevated levels can indicate high disease burden
• Albumin - a protein that reflects overall health status
• Lactate dehydrogenase (LDH) - reflects tumor cell characteristics and prognosis
• Beta-2 microglobulin - another marker of tumor burden and prognosis

Cardiac Biomarker

• NT-proBNP or BNP - measures heart function, as some myeloma treatments can affect the heart

Genetic/Chromosomal Biomarkers (FISH Panel)

This is one of the most important tests for treatment planning. According to NCCN Guidelines, your bone marrow plasma cells should be tested for:

High-Risk Features:

• del(17p13) - deletion of chromosome 17 (loss of the p53 tumor suppressor gene) = very high risk
• t(4;14) - translocation between chromosomes 4 and 14 = high risk
• t(14;16) - translocation between chromosomes 14 and 16 = high risk
• t(14;20) - translocation between chromosomes 14 and 20 = high risk

Other Important Markers:

• 1q21 gain/amplification - extra copies of chromosome 1 = increased risk of progression
• del(13) - deletion of chromosome 13 = may indicate more aggressive disease
• 1p deletion - loss of part of chromosome 1
• t(11;14) - translocation between chromosomes 11 and 14 = lower risk compared to others

TP53 Mutation Testing:

• Next-generation sequencing (NGS) to detect TP53 mutations, which indicate high-risk disease

Why These Biomarkers Matter

For Diagnosis: These tests confirm you have myeloma and rule out other conditions.

For Prognosis: Genetic markers like del(17p13) and t(4;14) help predict how aggressive your myeloma is and how it might respond to treatment.

For Treatment Selection: Your specific biomarkers guide which drugs your oncologist recommends. For example, certain genetic features may make you a better candidate for specific targeted therapies or clinical trials.

For Monitoring: Blood protein tests (M protein, free light chains) are repeated regularly—often every 3 months—to track whether treatment is working.

Testing During Treatment

According to NCCN Guidelines, follow-up biomarker testing typically includes:

• CBC with differential (complete blood count)
• Free light chain assay
• Immunoglobulin and M protein levels
• 24-hour urine protein and light chains
• Blood chemistry panel (kidney function, calcium, etc.)

Questions to Ask Your Oncology Team

1. Which FISH abnormalities did my myeloma cells show, and what do they mean for my prognosis?
2. What is my current M protein level, and how often will it be monitored?
3. Do I have any high-risk genetic features that would change my treatment recommendations?
4. How will you use my biomarker results to decide if my treatment is working?
5. Are there any biomarker tests that might help me qualify for a clinical trial?
6. If my biomarkers show progression, what treatment options would be available?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.